Oppenheimer lowered the firm’s price target on Apellis to $75 from $88 and Keeps an Outperform rating on the shares. While the firm is not ruling out an eventual approval for Syfovre, the firm sees a longer path towards educating the authorities on the evidence linking the drug’s benefit to functional benefit, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on APLS:
- Apellis Provides Update on Ongoing Regulatory Review of Pegcetacoplan for GA in the European Union
- Apellis says EMPAVELI provided long-term control of PNH
- EMPAVELI® (pegcetacoplan) Provided Long-Term Control of PNH in New Data Presented at ASH Annual Meeting
- Apellis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Lululemon downgraded, Datadog initiated: Wall Street’s top analyst calls